PLRZ Polyrizon Ltd.
Listings ·
Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months.
Polyrizon closed about $4.0 million from a registered direct offering and a concurrent private placement sold to one institutional investor, at $12.00 per unit. Aegis Capital Corp. acted as placement agent, and its fee took 8% of the registered portion.
Expected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.1 million | $534,000 |
| Net income (loss) | -$3.3 million | -$1.5 million |
| Cash from operations | -$4.5 million | -$1.1 million |
| Cash and equivalents | $1.3 million | $2.6 million |
Our latest story on this, dated Sep 4, 2026: "Polyrizon closes $4.0 million registered direct offering and private placement at $12.00". The story links the filing or release it is based on. Read the story.
Polyrizon Ltd. trades under the ticker PLRZ on NASDAQ.
Polyrizon Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Polyrizon Ltd. is 1893645. Its filings are on SEC EDGAR.
1,608,266 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-25.
Our directory records Polyrizon Ltd. under Israel.
Our directory classifies Polyrizon Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Polyrizon Ltd. is IL0011814113.
aibio.space lists Polyrizon Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
Polyrizon Ltd. reported a net loss of $3.3 million for the fiscal year ended Dec 31, 2025, and used $4.5 million of cash in operations, per its annual report to the SEC.
$2.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.3 million in cash at Dec 31, 2025, per its 20-F.
Our latest story on Polyrizon, dated Sep 28, 2026: "Polyrizon reports $8,410 thousand in cash at June 30, 2026". Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months. Source.
Our latest listing story, dated Sep 28, 2026: "Polyrizon reports $8,410 thousand in cash at June 30, 2026". Polyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months. Source.
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 6-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio